
|Articles|February 1, 2005
Imiquimod may potentiate melanoma vaccine effect
Newport Beach, Calif. — The immune response modifier imiquimod (Aldara, 3M Pharmaceuticals) may have a role as an enhancer of other immunotherapies for melanoma, Noah Craft, M.D., Ph.D. said here at the annual meeting of the Pacific Dermatologic Association (PDA).
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Highlighting Major Breakthroughs for Atopic Dermatitis and Psoriasis in 2025
2
First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA
3
Topicals Demonstrate Targeted Control Across 3 Distinct Atopic Dermatitis Cases
4
Balancing Pathophysiology and Patient Lifestyle in Acne Management: Part 2
5

















